Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?

ABSTRACT Zika virus caught the world by surprise by its rapid spread and frightening disease outcomes. This major epidemic motivated many scientists to focus their attention on controlling this emerging pathogen. As many as 45 vaccine candidates are being developed, but progress in the antiviral are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Devika Sirohi, Richard J. Kuhn
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2017
Materias:	Zika virus antiviral agents neurodegeneration NMDAR memantine Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/087799d59f7b43c6a462dc9d8246d579
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:087799d59f7b43c6a462dc9d8246d579
record_format	dspace
spelling	oai:doaj.org-article:087799d59f7b43c6a462dc9d8246d5792021-11-15T15:51:31ZCan an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?10.1128/mBio.00916-172150-7511https://doaj.org/article/087799d59f7b43c6a462dc9d8246d5792017-07-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00916-17https://doaj.org/toc/2150-7511ABSTRACT Zika virus caught the world by surprise by its rapid spread and frightening disease outcomes. This major epidemic motivated many scientists to focus their attention on controlling this emerging pathogen. As many as 45 vaccine candidates are being developed, but progress in the antiviral arena has been slower. In a recent article (mBio 8:e00350-17, 2017, https://doi.org/10.1128/mBio.00350-17 ), Costa and colleagues showed that an FDA-approved drug used to treat Alzheimer’s disease may moderate Zika virus-induced neuronal damage. This work is based on the premise that overstimulation of N-methyl-d-aspartate receptors (NMDARs) may drive neurodegeneration and that this may be responsible for neuronal cell death associated with Zika virus infection of the central nervous system (CNS). Thus, blockage of the NMDAR channel activity with FDA-approved memantine or other antagonists may reduce neurological complications associated with Zika virus infection. Repurposing a preapproved drug and targeting the host represent intriguing strategies and yet require more analysis prior to moving into clinical trials.Devika SirohiRichard J. KuhnAmerican Society for MicrobiologyarticleZika virusantiviral agentsneurodegenerationNMDARmemantineMicrobiologyQR1-502ENmBio, Vol 8, Iss 3 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Zika virus antiviral agents neurodegeneration NMDAR memantine Microbiology QR1-502
spellingShingle	Zika virus antiviral agents neurodegeneration NMDAR memantine Microbiology QR1-502 Devika Sirohi Richard J. Kuhn Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
description	ABSTRACT Zika virus caught the world by surprise by its rapid spread and frightening disease outcomes. This major epidemic motivated many scientists to focus their attention on controlling this emerging pathogen. As many as 45 vaccine candidates are being developed, but progress in the antiviral arena has been slower. In a recent article (mBio 8:e00350-17, 2017, https://doi.org/10.1128/mBio.00350-17 ), Costa and colleagues showed that an FDA-approved drug used to treat Alzheimer’s disease may moderate Zika virus-induced neuronal damage. This work is based on the premise that overstimulation of N-methyl-d-aspartate receptors (NMDARs) may drive neurodegeneration and that this may be responsible for neuronal cell death associated with Zika virus infection of the central nervous system (CNS). Thus, blockage of the NMDAR channel activity with FDA-approved memantine or other antagonists may reduce neurological complications associated with Zika virus infection. Repurposing a preapproved drug and targeting the host represent intriguing strategies and yet require more analysis prior to moving into clinical trials.
format	article
author	Devika Sirohi Richard J. Kuhn
author_facet	Devika Sirohi Richard J. Kuhn
author_sort	Devika Sirohi
title	Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
title_short	Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
title_full	Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
title_fullStr	Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
title_full_unstemmed	Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
title_sort	can an fda-approved alzheimer’s drug be repurposed for alleviating neuronal symptoms of zika virus?
publisher	American Society for Microbiology
publishDate	2017
url	https://doaj.org/article/087799d59f7b43c6a462dc9d8246d579
work_keys_str_mv	AT devikasirohi cananfdaapprovedalzheimersdrugberepurposedforalleviatingneuronalsymptomsofzikavirus AT richardjkuhn cananfdaapprovedalzheimersdrugberepurposedforalleviatingneuronalsymptomsofzikavirus
_version_	1718427317105065984

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?

Ejemplares similares